Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA7 | P43166 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18662398 | 1.00 | TSHR (0.30) | TSHRMAPK1CA12CA1CA2 | |
| SCHEMBL17286497 | 0.88 | CA12 (0.33) | TSHRMAPK1CA12CA1CA2 | |
| SCHEMBL18662404 | 0.88 | CA12 (0.33) | TSHRMAPK1CA12CA1CA2 | |
| SCHEMBL18662408 | 0.87 | CAT (0.42) | — | |
| SCHEMBL18662410 | 0.87 | CAT (0.42) | — | |
| SCHEMBL23130216 | 0.85 | MTNR1A (0.40) | MAPK1CA12CA1CA2CA7 | |
| SCHEMBL17347651 | 0.85 | MTNR1A (0.40) | MAPK1CA12CA1CA2CA7 | |
| SCHEMBL17286513 | 0.84 | POLB (0.31) | TSHRMAPK1 | |
| SCHEMBL18662441 | 0.84 | POLB (0.31) | TSHRMAPK1 | |
| SCHEMBL23129929 | 0.83 | MTNR1B (0.42) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3145936-B1 | BORONIC ACID DERIVATIVES AND THERAPEUTIC USES THEREOF | QPEX BIOPHARMA INC (US) | 2020-09-30 | — | — | EP | disclosed |
| EP-3145936-B1 | BORONIC ACID DERIVATIVES AND THERAPEUTIC USES THEREOF | QPEX BIOPHARMA INC (US) | 2020-09-30 | — | — | EP | disclosed |
| US-9963467-B2 | Boronic acid derivatives and therapeutic uses thereof | REMPEX PHARMACEUTICALS, INC. (US) | 2018-05-08 | — | — | US | disclosed |
| US-9963467-B2 | Boronic acid derivatives and therapeutic uses thereof | REMPEX PHARMACEUTICALS, INC. (US) | 2018-05-08 | — | — | US | disclosed |
| US-20170088561-A1 | BORONIC ACID DERIVATIVES AND THERAPEUTIC USES THEREOF | QPEX BIOPHARMA, INC. | 2017-03-30 | — | — | US | disclosed |
| US-20170088561-A1 | BORONIC ACID DERIVATIVES AND THERAPEUTIC USES THEREOF | QPEX BIOPHARMA, INC. | 2017-03-30 | — | — | US | disclosed |
| WO-2015179308-A1 | BORONIC ACID DERIVATIVES AND THERAPEUTIC USES THEREOF | REMPEX PHARMACEUTICALS, INC. (US) | 2015-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170088561-A1 | BORONIC ACID DERIVATIVES AND THERAPEUTIC USES THEREOF | BCL6B, BTD, BCL6 | TSHR 1972/4885MAPK1 2368/4885CA12 258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.